Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects

Editorial Material Oncology

Autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) in glioblastoma: Breakthrough or fata morgana?

Matthias Preusser et al.

NEURO-ONCOLOGY (2023)

Article Oncology

Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma A Phase 3 Prospective Externally Controlled Cohort Trial

Linda M. Liau et al.

Summary: The study shows that adding autologous tumor lysate-loaded dendritic cell vaccine (DCVax L) to standard of care can extend the survival of patients with glioblastoma.

JAMA ONCOLOGY (2023)

Add to Collection

Article Oncology

The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas

Atsushi Natsume et al.

Summary: DS-1001, an oral brain-penetrant mutant IDH1 selective inhibitor, demonstrated good tolerability and brain distribution in patients with recurrent/progressive IDH1-mutant glioma. It showed efficacy in tumor response and further studies are ongoing to evaluate its effectiveness in other types of gliomas.

NEURO-ONCOLOGY (2023)

Add to Collection

Review Oncology

Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement

Stephen J. Bagley et al.

Summary: This article reviews the limited therapeutic advances for glioblastoma and the failure of recent clinical trials, and emphasizes the need for improvement in clinical trial conduct. Challenges related to clinical trial eligibility criteria and trial design in glioblastoma are identified, and data-driven analysis of current glioblastoma clinical trials is provided.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Review Clinical Neurology

Advances in Immunotherapies for Gliomas

Michael Zhang et al.

Summary: This article summarizes the current clinical trials of immunotherapy-based treatment for glioblastoma. It evaluates the leading immunotherapy paradigms, discusses the encountered barriers, and explores future research directions. The findings suggest that while the current trials have not shown improvement in survival outcomes, they have demonstrated the safety and potential of these strategies, calling for further adaptive studies and larger-scale trials.

CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2022)

Add to Collection

Article Oncology

Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors

Francois Doz et al.

Summary: In patients with TRK fusion-positive CNS tumors, larotrectinib demonstrated rapid and durable responses, high disease control rate, and a favorable safety profile.

NEURO-ONCOLOGY (2022)

Add to Collection

Article Oncology

Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study

Andrew B. Lassman et al.

Summary: The selective FGFR1-3 inhibitor infigratinib showed limited efficacy in patients with FGFR-altered recurrent gliomas, but it may provide durable disease control in patients with tumors harboring FGFR1 or FGFR3 point mutations or FGFR3-TACC3 fusions.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Review Oncology

Relevant pharmacologic interactions in the concurrent management of brain tumor-related epilepsy and venous thromboembolism: a systematic review

David Gritsch et al.

Summary: This study conducted a systematic review of the literature to summarize the evidence for potential drug interactions between DOACs and AEDs in brain tumor patients. The findings indicate low-level evidence of potential drug interactions between these medications.

JOURNAL OF NEURO-ONCOLOGY (2022)

Add to Collection

Review Oncology

Focused ultrasound for the treatment of glioblastoma

Jill W. Roberts et al.

Summary: This article reviews the key updates from the 2021 workshop on focused ultrasound in the treatment of glioblastoma, outlines next research steps, and provides relevant references.

JOURNAL OF NEURO-ONCOLOGY (2022)

Add to Collection

Review Clinical Neurology

Advances in local therapy for glioblastoma - taking the fight to the tumour

Thomas S. van Solinge et al.

Summary: This review discusses local therapies for glioblastoma, examining treatment of the resection cavity and other direct approaches to the tumor.

NATURE REVIEWS NEUROLOGY (2022)

Add to Collection

Article Oncology

Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter

Michael Lim et al.

Summary: The study evaluated the addition of the immune checkpoint inhibitor nivolumab (NIVO) to radiotherapy (RT) + temozolomide (TMZ) in newly diagnosed glioblastoma patients and found that it did not improve survival in these patients.

NEURO-ONCOLOGY (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Safety of [177Lu]Lu-NeoB treatment: a preclinical study characterizing absorbed dose and acute, early, and late organ toxicity

Eline A. M. Ruigrok et al.

Summary: This study investigated the radiotoxic effects of [Lu-177]Lu-NeoB and its impact on target organs. The kidneys were found to be the most significantly affected organ. Histological and blood analyses revealed kidney damage and altered biochemical markers.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

Add to Collection

Article Oncology

Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: Interim analysis (IA) results.

Yohann Loriot et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Intratumoral oncolytic herpes virus G47 increment for residual or recurrent glioblastoma: a phase 2 trial

Tomoki Todo et al.

Summary: A crucial clinical trial demonstrates that repeated tumor-administration of oncolytic herpes virus G47 Increment in residual or recurrent glioblastoma leads to improved survival rates and a safe profile.

NATURE MEDICINE (2022)

Add to Collection

Article Oncology

Nanomedicine for glioblastoma: Progress and future prospects

Imran Khan et al.

Summary: Glioblastoma, the most aggressive form of brain tumor, has poor prognosis despite aggressive treatment strategies. The blood-brain barrier (BBB) hinders drug delivery to the tumor site, but nanomedicine strategies hold promise in enhancing drug permeability.

SEMINARS IN CANCER BIOLOGY (2022)

Add to Collection

Review Biotechnology & Applied Microbiology

Ultrasound-assisted brain delivery of nanomedicines for brain tumor therapy: advance and prospect

Shuo Zhang et al.

Summary: Brain tumors pose a challenge, and effective drug delivery across the blood-brain barrier (BBB) is essential. Ultrasound-assisted brain delivery (UABD) technology combined with nanomedicines shows promise in enhancing therapeutic effects on brain tumors. However, research on UABD nanomedicines is still in its early stages, with unclear mechanisms and material design theories.

JOURNAL OF NANOBIOTECHNOLOGY (2022)

Add to Collection

Review Pharmacology & Pharmacy

A Historical Review of Brain Drug Delivery

William M. Pardridge

Summary: This article reviews the history of brain drug delivery and discusses different technologies and methods. Due to the restricted transport across the blood-brain barrier, FDA-approved drugs for the central nervous system are generally limited to lipid-soluble small molecules.

PHARMACEUTICS (2022)

Add to Collection

Review Neurosciences

Effects of Sound Interventions on the Permeability of the Blood-Brain Barrier and Meningeal Lymphatic Clearance

Sean Sachdeva et al.

Summary: This review discusses the effects of music/sound on blood-brain barrier permeability and meningeal lymphatic clearance, highlighting its potential positive impact on brain and body functions. However, there is limited knowledge regarding the systematic investigation and outcomes of using music/sound in medical interventions. Further research is needed to explore the potential of music/sound in healthcare.

BRAIN SCIENCES (2022)

Add to Collection

Review Oncology

Boron Neutron Capture Therapy: Clinical Application and Research Progress

Xiang Cheng et al.

Summary: Boron neutron capture therapy (BNCT) is an effective binary modality for treating malignancies. It has been used in various cancer types, but there are still challenges that need to be addressed through further research and improvement.

CURRENT ONCOLOGY (2022)

Add to Collection

Article Oncology

Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143

Antonio Omuro et al.

Summary: The study evaluated the safety and efficacy of nivolumab combined with radiotherapy and temozolomide in newly diagnosed glioblastoma. The results showed that this combination therapy was feasible, with no new safety signals. There was a slight difference in overall survival between patients with different MGMT methylation statuses.

NEURO-ONCOLOGY ADVANCES (2022)

Add to Collection

Review Oncology

A review of glioblastoma immunotherapy

Ravi Medikonda et al.

Summary: Current immunotherapy treatments for glioblastoma, including checkpoint inhibitors and vaccine therapy, have shown disappointing results in clinical trials due to the highly immunosuppressive environment and therapy resistance mechanisms of the tumor. Ongoing research is focusing on exploring combination therapies and novel treatment strategies beyond immune checkpoint therapies, as well as establishing synergy between immunotherapy and current standard of care to improve treatment outcomes. Recent advances in personalized neoantigen vaccines suggest a shift towards personalized, patient-specific treatment for glioblastoma.

JOURNAL OF NEURO-ONCOLOGY (2021)

Add to Collection

Review Oncology

Re-irradiation for high-grade gliomas: Has anything changed?

Sonia Garcia-Cabezas et al.

Summary: Management after recurrence or progression of high-grade gliomas remains a challenge, with re-irradiation being considered as an option. Decision-making needs to be individualized, taking into account various factors.

WORLD JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

Lakshmi Nayak et al.

Summary: The study showed that pembrolizumab alone or in combination with bevacizumab had limited efficacy in the treatment of recurrent glioblastoma, failing to improve patient survival rates. Tumor immune biomarkers were not reliable predictors of treatment outcomes, while baseline dexamethasone use and certain tumor biomarkers may impact treatment efficacy.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Review Oncology

Local treatment for relapsing glioblastoma: A decision-making tree for choosing between reirradiation and second surgery

Silvia Scoccianti et al.

Summary: For circumscribed recurrent glioblastoma, a second surgery and reirradiation can be considered as local treatment strategies, taking into account patient's life expectancy, disease status, prognostic factors, and expected toxicity to determine the treatment plan.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)

Add to Collection

Review Clinical Neurology

The Efficacy of Dendritic Cell Vaccine for Newly Diagnosed Glioblastoma: A Meta-analysis of Randomized Controlled Studies

Long Tan et al.

Summary: The efficacy of dendritic cell vaccine for newly diagnosed glioblastoma remains controversial. A systematic review and meta-analysis found that dendritic cell vaccine did not show significant benefits for median overall survival, progression-free survival, or overall survival rate compared to control group in newly diagnosed glioblastoma.

CLINICAL NEUROPHARMACOLOGY (2021)

Add to Collection

Article Oncology

EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

Michael Weller et al.

Summary: The European Association of Neuro-Oncology (EANO) has released guidelines for the diagnosis, treatment, and follow-up of adult patients with diffuse gliomas, incorporating major changes in diagnostic algorithms based on the 2016 update of the WHO Classification of Tumors of the Central Nervous System, as well as evidence from recent large clinical trials.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

Add to Collection

Review Biotechnology & Applied Microbiology

Engineering precision nanoparticles for drug delivery

Michael J. Mitchell et al.

Summary: The development of nanoparticles has shown promising clinical applications, overcoming the limitations of therapeutic interventions and biological barriers. Precision therapies have enhanced treatment efficacy through personalized interventions. Advancements in nanoparticle design aim to optimize drug delivery, improving efficacy in general applications and enabling tailored designs for precision applications.

NATURE REVIEWS DRUG DISCOVERY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Hypoxia: The Cornerstone of Glioblastoma

Marta Domenech et al.

Summary: Glioblastoma is the most aggressive form of brain tumor in adults, with hypoxia-induced factor 1 (HIF-1) serving as an important driver of tumor progression by promoting angiogenesis, immunosuppression, and metabolic reprogramming. HIF-1 is not only regulated by oxygen levels but also by various oncogenic signaling pathways, and inhibiting the hypoxia pathway could be a crucial treatment alternative for GB patients.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Novel Dual PI3K/mTOR Inhibitor, Apitolisib (GDC-0980), Inhibits Growth and Induces Apoptosis in Human Glioblastoma Cells

Wioleta Justyna Omeljaniuk et al.

Summary: The study found that GDC-0980 can effectively inhibit the survival of human GBM cells and induce apoptosis, independent of ER stress-mediated DR5 activation. It is suggested that GDC-0980 may block the inhibitory effect on protein synthesis through inhibiting PERK expression, leading to an intensification of translation and an increase in apoptosis. Additionally, CHOP stimulates protein synthesis and increases apoptosis.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Clinical Neurology

CTNI-26. PHASE 2 STUDY OF DIANHYDROGALACTITOL (VAL-083) IN PATIENTS WITH MGMT-UNMETHYLATED, BEVACIZUMAB-NAÏVE GLIOBLASTOMA IN THE RECURRENT AND ADJUVANT SETTING

Barbara O'Brien et al.

NEURO-ONCOLOGY (2021)

Add to Collection

Article Clinical Neurology

RTID-03. DESIGN AND INITIATION OF PIVOTAL STUDIES FOR BERUBICIN, A NOVEL, POTENT TOPOISOMERASE II POISON FOR THE TREATMENT OF RECURRENT GLIOBLASTOMA MULTIFORME (GBM)

Sandra Silberman et al.

NEURO-ONCOLOGY (2021)

Add to Collection

Review Immunology

Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas

Jiayi Zeng et al.

Summary: The prognosis of malignant gliomas remains poor, with limited therapeutic options. Immunotherapy and oncolytic virotherapy are rapidly developing fields that hold promise for enhancing cancer treatment effectiveness.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Review Immunology

Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End

Angeliki Datsi et al.

Summary: Dendritic cell vaccination (DCV) is a promising immunotherapy for treating glioblastomas, with numerous trials showing potential but some controlled studies failing to detect a survival benefit. Further exploration is needed to fully understand the potential of this therapeutic approach.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Review Pharmacology & Pharmacy

Nanotherapeutics for Nose-to-Brain Drug Delivery: An Approach to Bypass the Blood Brain Barrier

David Lee et al.

Summary: The blood-brain barrier poses a challenge to delivering therapeutic molecules to the brain, but nose-to-brain drug delivery bypasses this barrier and increases drug concentration in the brain, improving treatment efficacy. Recent advances in nanotechnology have played a significant role in this area.

PHARMACEUTICS (2021)

Add to Collection

Review Oncology

Second surgery for progressive glioblastoma: a multi-centre questionnaire and cohort-based review of clinical decision-making and patient outcomes in current practice

P. M. Brennan et al.

Summary: The prognosis for glioblastoma is poor, with limited treatment options at progression. This study aimed to examine variations in surgical management at progression and propose consensus guidelines to reduce heterogeneity in decision making. Current practice showed variation in patient selection for second surgery, with a focus on maintaining or improving patient quality of life, and no association between time to second surgery and time to death.

JOURNAL OF NEURO-ONCOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

A vaccine targeting mutant IDH1 in newly diagnosed glioma

Michael Platten et al.

Summary: Mutated isocitrate dehydrogenase 1 (IDH1) defines a molecularly distinct subtype of diffuse glioma. The most common IDH1 mutation in gliomas affects codon 132 and encodes IDH1(R132H), which harbours a shared clonal neoepitope that is presented on major histocompatibility complex (MHC) class II. An IDH1(R132H)-specific peptide vaccine (IDH1-vac) induces specific therapeutic T helper cell responses that are effective against IDH1(R132H)+ tumours.

NATURE (2021)

Add to Collection

Article Oncology

A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study

Hao-Wen Sim et al.

Summary: The study evaluated the synergistic effect of veliparib with radiation and temozolomide in patients with MGMT-unmethylated glioblastoma. The veliparib-containing regimen showed feasibility and tolerability, but did not demonstrate significant clinical benefit compared to the standard treatment. Adverse events were primarily thrombocytopenia and neutropenia.

NEURO-ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas

G. K. Friedman et al.

Summary: The study conducted a phase 1 trial of G207 in children and adolescents with recurrent or progressive supratentorial brain tumors, showing an acceptable adverse-event profile and evidence of responses. G207 was able to convert immunologically cold tumors to hot.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Blood-brain barrier opening by intracarotid artery hyperosmolar mannitol induces sterile inflammatory and innate immune responses

Scott R. Burks et al.

Summary: Intracarotid arterial hyperosmolar mannitol (ICAHM) is effective and safe for treating central nervous system malignancies by disrupting the blood-brain barrier, but it can induce a transient neuroinflammatory response.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Add to Collection

Meeting Abstract Oncology

Preliminary results of the abemaciclib arm in the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A phase II platform trial using Bayesian adaptive randomization.

Eudocia Quant Lee et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Meeting Abstract Oncology

EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with temozolomide-based radiochemotherapy versus temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.

Patrick Roth et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Review Oncology

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

David N. Louis et al.

Summary: The fifth edition of the WHO Classification of Tumors of the Central Nervous System integrates molecular diagnostics into CNS tumor classification, introduces different approaches to tumor nomenclature and grading, and emphasizes the importance of integrated diagnoses and layered reports.

NEURO-ONCOLOGY (2021)

Add to Collection

Article Oncology

IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification

Giulia Berzero et al.

Summary: The study finds that IDHwt grade II gliomas have a relatively higher survival rate, while patients meeting the definition of molecular glioblastoma have a shorter survival period. The majority of patients meeting the cIMPACT criteria have isolated TERT promoter mutations, which are not significantly associated with poor outcomes.

NEURO-ONCOLOGY (2021)

Add to Collection

Article Clinical Neurology

Quality of patient-reported outcome reporting according to the CONSORT statement in randomized controlled trials with glioblastoma patients

Louis Garnier et al.

Summary: The study evaluated adherence to the CONSORT-PRO statement in reporting RCTs addressing the treatment of patients with glioblastoma. Findings showed overall poor use of the CONSORT-PRO statement, with particular deficiencies in reporting data collection and analysis methods. Despite the importance of measuring PROs in patients with glioblastoma, the employment of the CONSORT-PRO statement is lacking in RCTs.

NEURO-ONCOLOGY PRACTICE (2021)

Add to Collection

Article Oncology

A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors

Markus Joerger et al.

INVESTIGATIONAL NEW DRUGS (2020)

Add to Collection

Article Oncology

A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study

Sarah Lapointe et al.

INVESTIGATIONAL NEW DRUGS (2020)

Add to Collection

Article Oncology

INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

Martin van den Bent et al.

NEURO-ONCOLOGY (2020)

Add to Collection

Review Oncology

Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients

Eudocia Q. Lee et al.

NEURO-ONCOLOGY (2020)

Add to Collection

Article Oncology

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial

David A. Reardon et al.

JAMA ONCOLOGY (2020)

Add to Collection

Article Oncology

Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein

Holger Fischer et al.

NEURO-ONCOLOGY (2020)

Add to Collection

Review Oncology

How did lomustine become standard of care in recurrent glioblastoma?

Michael Weller et al.

CANCER TREATMENT REVIEWS (2020)

Add to Collection

Review Immunology

Efficacy and safety of dendritic cell vaccines for patients with glioblastoma: A meta-analysis of randomized controlled trials

Li Lv et al.

INTERNATIONAL IMMUNOPHARMACOLOGY (2020)

Add to Collection

Review Oncology

Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review

Michael A. Vogelbaum et al.

NEURO-ONCOLOGY (2020)

Add to Collection

Review Immunology

Glioblastoma Immune Landscape and the Potential of New Immunotherapies

Thomas Daubon et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Oncology

Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study

Giuseppe Lombardi et al.

CANCERS (2020)

Add to Collection

Article Oncology

Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma A Randomized Clinical Trial

Timothy F. Cloughesy et al.

JAMA ONCOLOGY (2020)

Add to Collection

Article Oncology

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017

Quinn T. Ostrom et al.

NEURO-ONCOLOGY (2020)

Add to Collection

Review Oncology

The blood-brain barrier and blood-tumour barrier in brain tumours and metastases

Costas D. Arvanitis et al.

NATURE REVIEWS CANCER (2020)

Add to Collection

Article Oncology

N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma

Wolfgang Wick et al.

NEURO-ONCOLOGY (2019)

Add to Collection

Article Oncology

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial

Patrick Y. Wen et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

Timothy F. Cloughesy et al.

NATURE MEDICINE (2019)

Add to Collection

Article Oncology

Accelerated progression of IDH mutant glioma after first recurrence

Julie J. Miller et al.

NEURO-ONCOLOGY (2019)

Add to Collection

Review Oncology

The unique invasiveness of glioblastoma and possible drug targets on extracellular matrix

Adam Hatoum et al.

CANCER MANAGEMENT AND RESEARCH (2019)

Add to Collection

Article Oncology

A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma

Patrick Y. Wen et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection

Review Immunology

Mechanisms of immunotherapy resistance: lessons from glioblastoma

Christopher M. Jackson et al.

NATURE IMMUNOLOGY (2019)

Add to Collection

Review Cell Biology

Fibroblast Growth Factor Receptor Functions in Glioblastoma

Ana Jimenez-Pascual et al.

CELLS (2019)

Add to Collection

Article Oncology

Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma

Daniel Felix Fleischmann et al.

RADIOTHERAPY AND ONCOLOGY (2019)

Add to Collection

Review Immunology

CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy

Michael C. Burger et al.

FRONTIERS IN IMMUNOLOGY (2019)

Add to Collection

Article Oncology

Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma

Stefano Indraccolo et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection

Article Oncology

Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study

Pascale Fabbro-Peray et al.

JOURNAL OF NEURO-ONCOLOGY (2019)

Add to Collection

Review Oncology

Re-irradiation for recurrent glioblastoma (GBM): a systematic review and meta-analysis

Farasat Kazmi et al.

JOURNAL OF NEURO-ONCOLOGY (2019)

Add to Collection

Article Oncology

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial

Giuseppe Lombardi et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Oncology

PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity

Shiv K. Gupta et al.

FRONTIERS IN ONCOLOGY (2019)

Add to Collection

Article Clinical Neurology

Reirradiation of recurrent high-grade glioma and development of prognostic scores for progression and survival

Christopher H. Chapman et al.

NEURO-ONCOLOGY PRACTICE (2019)

Add to Collection

Article Oncology

Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment

Xiao-Tang Kong et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)

Add to Collection

Article Oncology

Treatment and survival of glioblastoma patients in Denmark: The Danish Neuro-Oncology Registry 2009-2014

Steinbjorn Hansen et al.

JOURNAL OF NEURO-ONCOLOGY (2018)

Add to Collection

Article Oncology

Outcomes after second surgery for recurrent glioblastoma: a retrospective case-control study

Alysson Wann et al.

JOURNAL OF NEURO-ONCOLOGY (2018)

Add to Collection

Article Clinical Neurology

Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas

Sherise D. Ferguson et al.

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2018)

Add to Collection

Article Medicine, Research & Experimental

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

Linda M. Liau et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2018)

Add to Collection

Review Oncology

Current state of immunotherapy for glioblastoma

Michael Lim et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Recurrent Glioblastoma Treated with Recombinant Poliovirus

Annick Desjardins et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Review Biochemistry & Molecular Biology

Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies

Zhenyi An et al.

ONCOGENE (2018)

Add to Collection

Review Clinical Neurology

The Survival Effect of Repeat Surgery at Glioblastoma Recurrence and its Trend: A Systematic Review and Meta-Analysis

Victor M. Lu et al.

WORLD NEUROSURGERY (2018)

Add to Collection

Article Multidisciplinary Sciences

The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models

Stephen T. Durant et al.

SCIENCE ADVANCES (2018)

Add to Collection

Meeting Abstract Oncology

Phase I clinical trials evaluating olaparib in combination with radiotherapy (RT) and/or temozolomide (TMZ) in glioblastoma patients: Results of OPARATIC and PARADIGM phase I and early results of PARADIGM-2.

Anthony J. Chalmers et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Oncology

Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma

Jennie W. Taylor et al.

JOURNAL OF NEURO-ONCOLOGY (2018)

Add to Collection

Review Cell & Tissue Engineering

Current status and potential challenges of mesenchymal stem cell-based therapy for malignant gliomas

Qing Zhang et al.

STEM CELL RESEARCH & THERAPY (2018)

Add to Collection

Review Oncology

Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE

Brian M. Alexander et al.

CLINICAL CANCER RESEARCH (2018)

Add to Collection

Article Neurosciences

Gastrin-Releasing Peptide Receptor Knockdown Induces Senescence in Glioblastoma Cells

Pamela Rossi Menegotto et al.

MOLECULAR NEUROBIOLOGY (2017)

Add to Collection

Article Neurosciences

Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses

Wen Cheng et al.

MOLECULAR NEUROBIOLOGY (2017)

Add to Collection

Review Oncology

Response Assessment in Neuro-Oncology Clinical Trials

Patrick Y. Wen et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Review Oncology

Recent advances of highly selective CDK4/6 inhibitors in breast cancer

Hanxiao Xu et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)

Add to Collection

Review Oncology

Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape

Benjamin M. Ellingson et al.

JOURNAL OF NEURO-ONCOLOGY (2017)

Add to Collection

Article Oncology

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller et al.

LANCET ONCOLOGY (2017)

Add to Collection

Review Oncology

European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma

Andrea Pace et al.

LANCET ONCOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Lomustine and Bevacizumab in Progressive Glioblastoma

Wolfgang Wick et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Cell Biology

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

Donald M. O'Rourke et al.

SCIENCE TRANSLATIONAL MEDICINE (2017)

Add to Collection

Review Oncology

Delivery of Biologics Across the Blood-Brain Barrier with Molecular Trojan Horse Technology

William M. Pardridge

BIODRUGS (2017)

Add to Collection

Article Oncology

GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status

P. Perez-Segura et al.

CLINICAL & TRANSLATIONAL ONCOLOGY (2016)

Add to Collection

Article Oncology

The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing

Teresa Helsten et al.

CLINICAL CANCER RESEARCH (2016)

Add to Collection

Article Oncology

A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study

H. Ian Robins et al.

JOURNAL OF NEURO-ONCOLOGY (2016)

Add to Collection

Article Oncology

Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma

Shiv K. Gupta et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)

Add to Collection

Article Oncology

Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma

Nan Ji et al.

ONCOTARGET (2016)

Add to Collection

Article Oncology

Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma

Shiv K. Gupta et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)

Add to Collection

Review Clinical Neurology

Second surgery for recurrent glioblastoma: A concise overview of the current literature

Nicola Montemurro et al.

CLINICAL NEUROLOGY AND NEUROSURGERY (2016)

Add to Collection

Review Pharmacology & Pharmacy

CSF, blood-brain barrier, and brain drug delivery

William M. Pardridge

EXPERT OPINION ON DRUG DELIVERY (2016)

Add to Collection

Review Clinical Neurology

Blood-brain barrier, cytotoxic chemotherapies and glioblastoma

Antonin Drean et al.

EXPERT REVIEW OF NEUROTHERAPEUTICS (2016)

Add to Collection

Article Oncology

Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial

Bogdana Suchorska et al.

NEURO-ONCOLOGY (2016)

Add to Collection

Article Oncology

Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma

Lee A. Wheeler et al.

NEURO-ONCOLOGY (2016)

Add to Collection

Article Medicine, General & Internal

Palbociclib and Letrozole in Advanced Breast Cancer

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Medicine, General & Internal

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

Christine E. Brown et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Review Cell Biology

Glioblastoma, hypoxia and autophagy: a survival-prone 'menage-a-trois'

Soha Jawhari et al.

CELL DEATH & DISEASE (2016)

Add to Collection

Article Oncology

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma

Xiaoman Li et al.

ONCOTARGET (2016)

Add to Collection

Review Clinical Neurology

Blood-brain barrier, cytotoxic chemotherapies and glioblastoma

Antonin Drean et al.

EXPERT REVIEW OF NEUROTHERAPEUTICS (2016)

Add to Collection

Editorial Material Pharmacology & Pharmacy

Proteasome inhibitors Commentary

Beverly A. Teicher et al.

BIOCHEMICAL PHARMACOLOGY (2015)

Add to Collection

Article Oncology

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group

Hideho Okada et al.

LANCET ONCOLOGY (2015)

Add to Collection

Review Biotechnology & Applied Microbiology

Hypoxia-Inducible Factor-1 in Physiological and Pathophysiological Angiogenesis: Applications and Therapies

Agnieszka Zimna et al.

BIOMED RESEARCH INTERNATIONAL (2015)

Add to Collection

Article Oncology

A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K

Daniel J. Ma et al.

NEURO-ONCOLOGY (2015)

Add to Collection

Review Oncology

Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials

Benjamin M. Ellingson et al.

NEURO-ONCOLOGY (2015)

Add to Collection

Article Oncology

Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors

Woondong Jeong et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)

Add to Collection

Review Oncology

The role of cytoreductive surgery in the management of progressive glioblastoma

Timothy Charles Ryken et al.

JOURNAL OF NEURO-ONCOLOGY (2014)

Add to Collection

Article Oncology

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

Walter Taal et al.

LANCET ONCOLOGY (2014)

Add to Collection

Article Medicine, General & Internal

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

Mark R. Gilbert et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Letter Medicine, General & Internal

Bevacizumab for Newly Diagnosed Glioblastoma Reply

Olivier L. Chinot et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Article Clinical Neurology

Integration of palliative care into the neuro-oncology practice: patterns in the United States

Tobias Walbert

NEURO-ONCOLOGY PRACTICE (2014)

Add to Collection

Article Medicine, General & Internal

Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma

Olivier L. Chinot et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Article Biochemistry & Molecular Biology

The Somatic Genomic Landscape of Glioblastoma

Cameron W. Brennan et al.

CELL (2013)

Add to Collection

Article Oncology

Arylsulfonamide KCN1 Inhibits In Vivo Glioma Growth and Interferes with HIF Signaling by Disrupting HIF-1α Interaction with Cofactors p300/CBP

Shaoman Yin et al.

CLINICAL CANCER RESEARCH (2012)

Add to Collection

Article Oncology

The CareGiver Oncology Quality of Life questionnaire (CarGOQoL): Development and validation of an instrument to measure the quality of life of the caregivers of patients with cancer

Patricia Minaya et al.

EUROPEAN JOURNAL OF CANCER (2012)

Add to Collection

Article Oncology

NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality

Roger Stupp et al.

EUROPEAN JOURNAL OF CANCER (2012)

Add to Collection

Review Oncology

Phase 2 trial design in neuro-oncology revisited: a report from the RANO group

Evanthia Galanis et al.

LANCET ONCOLOGY (2012)

Add to Collection

Letter Oncology

Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error?

Carmen Balana et al.

CLINICAL & TRANSLATIONAL ONCOLOGY (2011)

Add to Collection

Article Multidisciplinary Sciences

Degradation of HIF-1alpha under Hypoxia Combined with Induction of Hsp90 Polyubiquitination in Cancer Cells by Hypericin: a Unique Cancer Therapy

Tilda Barliya et al.

PLOS ONE (2011)

Add to Collection

Article Oncology

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

Roel G. W. Verhaak et al.

CANCER CELL (2010)

Add to Collection

Article Oncology

Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study

James R. Perry et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

Add to Collection

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

Add to Collection

Article Oncology

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

Henry S. Friedman et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

Add to Collection

Review Clinical Neurology

Novel Drug Delivery Strategies in Neuro-Oncology

Dani S. Bidros et al.

NEUROTHERAPEUTICS (2009)

Add to Collection

Article Oncology

REPLICATION-DEPENDENT RADIOSENSITIZATION OF HUMAN GLIOMA CELLS BY INHIBITION OF POLY(ADP-RIBOSE) POLYMERASE: MECHANISMS AND THERAPEUTIC POTENTIAL

Fiona A. Dungey et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)

Add to Collection

Article Oncology

A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia

Stanley K. Liu et al.

RADIOTHERAPY AND ONCOLOGY (2008)

Add to Collection

Article Oncology

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme

SM Chang et al.

INVESTIGATIONAL NEW DRUGS (2005)

Add to Collection

Article Medicine, General & Internal

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

R Stupp et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

Add to Collection

Article Oncology

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

M Brada et al.

ANNALS OF ONCOLOGY (2001)

Add to Collection

Article Oncology

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

WKA Yung et al.

BRITISH JOURNAL OF CANCER (2000)

Add to Collection

Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects

Related references

Export Citation

Share Paper